TL;DR: Biological age describes how old your body's tissues and systems appear to function, as opposed to chronological age, which simply counts years since birth. Epigenetic clocks are the most studied biological age tests; they measure DNA methylation, chemical tags on your DNA that shift in predictable patterns with age, at specific genomic sites. The first widely used clock, built by Steve Horvath, could estimate age within about 3.6 years across many tissue types (Horvath, Genome Biology, 2013). Newer "second-generation" clocks, including PhenoAge (Levine et al., Aging, 2018) and GrimAge (Lu et al., Aging, 2019), were trained to predict mortality and healthspan rather than chronological age alone, and both outperform simple age-based prediction in multiple cohorts. Beyond DNA methylation, researchers also measure biological age through telomere length, blood biomarker composites, and proteomic or "organ age" clocks. Direct-to-consumer epigenetic tests are now commercially available for roughly 100 to 300 US dollars, though clinical guidelines have not yet adopted any clock as a diagnostic standard. This article explains how these tests work, what the evidence supports, and where the science still has real gaps.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
What Is Biological Age and How Does It Differ From Chronological Age?
Chronological age is simple: it is the number of years since you were born, identical for everyone born on the same date. Biological age attempts to answer a different, harder question: given everything happening inside your cells, tissues, and organ systems, how old does your body actually behave, functionally and molecularly, regardless of the date on your birth certificate? Two 55-year-olds can have meaningfully different biological ages if one has spent decades exercising, sleeping well, and avoiding chronic disease while the other has accumulated more cellular damage, inflammation, and organ strain along the way.
The appeal of biological age testing is straightforward: chronological age treats everyone on the same calendar as identical, while biological age testing tries to capture the fact that aging is not a uniform, fixed-rate process, and that lifestyle, genetics, and environment all influence how quickly cells and tissues accumulate the molecular hallmarks of aging. Our companion piece on biological age measurement covers the broader landscape of testing approaches; this article focuses specifically on epigenetic clocks, currently the most heavily researched and widely commercialized category of biological age test.
What Is an Epigenetic Clock and How Does It Work?
Epigenetic clocks are built on DNA methylation, a chemical modification in which a methyl group attaches to specific locations on your DNA, typically at cytosine bases next to guanine bases, known as CpG sites. Methylation does not change your underlying genetic code; instead, it regulates whether nearby genes are turned on or off, functioning as part of the broader epigenetic system that controls gene expression without altering the DNA sequence itself. Critically for aging research, methylation levels at specific, identifiable CpG sites across the genome change in remarkably predictable, clock-like patterns as you age.
Researchers building an epigenetic clock start with blood or tissue samples from thousands of people of known chronological age, measure methylation at hundreds of thousands of CpG sites, and use statistical modeling to identify a subset of sites, typically several hundred, whose combined methylation pattern predicts age with strong accuracy. The resulting mathematical model, the clock, can then be applied to a new DNA sample to generate a predicted age, one that may run higher, lower, or roughly equal to the person's actual chronological age. A predicted age higher than chronological age is generally interpreted as accelerated biological aging; a lower predicted age suggests the opposite.
What Was the Horvath Clock and Why Was It a Breakthrough?
In 2013, biostatistician Steve Horvath published what became the most influential epigenetic clock to date, trained on methylation data spanning many different healthy tissue and cell types. What made the Horvath clock remarkable was not just its accuracy, a median error of about 3.6 years across the training data, but its versatility: unlike earlier, more limited methylation-age models built for a single tissue, Horvath's clock could estimate age accurately across nearly any tissue or cell type in the body, from skin and blood to brain and bone (Horvath, Genome Biology, 2013).
That versatility mattered enormously for the field, because it suggested the methylation-age relationship was tracking something close to a fundamental, body-wide aging process rather than a quirk specific to one tissue type. A separate, roughly contemporaneous clock built by Gregory Hannum and colleagues, trained primarily on blood samples, reached similar conclusions using an independent methodology and dataset, lending further credibility to the idea that methylation age was capturing a real, reproducible biological signal rather than a statistical artifact of one research group's data (Hannum et al., Molecular Cell, 2013). Together, these first-generation clocks established that it was possible to read something resembling an age signal directly out of a DNA sample, which opened the door to the more clinically ambitious clocks that followed.
What Are Second-Generation Clocks Like PhenoAge and GrimAge?
First-generation clocks like Horvath's were built and validated to predict chronological age itself, which is a strange target in one sense: chronological age is already known and free to obtain from a birth certificate, so a test that predicts it well is not, by itself, telling you anything about health risk. The field's second generation of clocks changed the target. Instead of training the model to predict chronological age, researchers trained new clocks to predict clinical biomarkers of physiological decline and, ultimately, mortality risk itself.
PhenoAge, developed by Morgan Levine and colleagues, was trained on a composite of clinical biomarkers linked to mortality, including markers of inflammation, kidney and liver function, and immune status, then mapped onto DNA methylation data, producing a methylation-based score that predicted all-cause mortality, cancer, and healthspan more strongly than chronological age or the original Horvath clock (Levine et al., Aging, 2018). GrimAge, developed by Ake Lu and colleagues, went a step further, training its methylation model directly against time-to-death and health outcome data, incorporating methylation-based surrogates for smoking pack-years and several plasma proteins associated with mortality risk; in validation cohorts, GrimAge outperformed both chronological age and earlier clocks as a predictor of lifespan and healthspan, including time to coronary heart disease and cancer (Lu et al., Aging, 2019).
More recently, the DunedinPACE clock took yet another approach, measuring not a single age estimate but the pace of aging, how fast a person is aging at the time of measurement, using repeated biomarker measurements collected from the same cohort of New Zealanders across two decades of the long-running Dunedin Study (Belsky et al., eLife, 2022). This built on earlier work from the same research group demonstrating that a person's rate of biological aging could be quantified in young adults, well before age-related disease was clinically apparent (Belsky et al., PNAS, 2015).
How Well Do Epigenetic Clocks Predict Mortality and Disease?
This is the question that matters most for anyone considering a test, and the evidence here is genuinely stronger than for most emerging biomarkers. A meta-analysis pooling multiple epigenetic clocks across several large cohorts found that DNA methylation age acceleration, meaning a predicted age higher than actual chronological age, was associated with increased risk of death from all causes, even after adjusting for chronological age and traditional risk factors (Chen et al., Aging, 2016). GrimAge in particular has shown a strong, consistent association with time to death across multiple independent cohorts and has outperformed other clocks and many conventional risk factors in head-to-head comparisons within the same studies (Lu et al., Aging, 2019).
It is worth being precise about what this evidence does and does not show. These are observational, associative findings: people whose methylation clocks run older than their chronological age have, on average, higher mortality and disease risk in the populations studied. This is a real and repeatedly replicated statistical association, not a demonstration that methylation changes themselves cause the excess risk, and it does not mean an individual's specific test result functions as a precise medical prediction the way a diagnostic test does. The clocks are population-level risk tools that have proven unusually good at their job, not individual crystal balls.
What Other Biological Age Testing Methods Exist Beyond Epigenetics?
Epigenetic clocks are the most heavily marketed biological age tests, but they are not the only approach researchers use. Telomere length, the protective caps on the ends of chromosomes that shorten with each cell division, was one of the earliest proposed biological aging markers and remains an active area of study, with telomere biology linked to cellular senescence and stress exposure over the lifespan (Blackburn et al., Science, 2015); our article on chronic stress and telomeres covers this relationship in more depth, including why telomere length has proven a noisier, less individually predictive marker than the newer epigenetic clocks.
Biomarker composite methods, such as the Klemera-Doubal method, calculate biological age from a panel of routine clinical blood values, things like blood pressure, cholesterol, glucose, and kidney function markers, combined through a statistical formula rather than through DNA analysis at all (Klemera and Doubal, Mechanisms of Ageing and Development, 2006). These composite scores have the advantage of using cheap, widely available lab values rather than specialized methylation sequencing, though they generally show somewhat weaker mortality prediction than the best second-generation epigenetic clocks in head-to-head comparisons. Newer proteomic clocks, which measure patterns across thousands of blood proteins rather than DNA methylation, and organ-specific "organ age" clocks, which attempt to estimate the biological age of individual organs like the heart, kidney, or brain separately, represent the newest and least clinically mature branch of this research, with promising early cohort results but far less validation history than Horvath, PhenoAge, or GrimAge.
Can You Get an Epigenetic Age Test as a Consumer, and What Does It Cost?
Yes. Several direct-to-consumer companies now offer epigenetic age testing, typically using a blood draw or saliva sample mailed to a lab, with results reported as a single estimated biological age alongside your chronological age, and sometimes a breakdown by clock type, since several companies report both a PhenoAge-style and a GrimAge-style estimate. Prices generally range from about 100 to 300 US dollars per test as of the time of writing, with some companies offering subscription models for repeated testing over time to track trends.
It is worth setting expectations correctly before ordering one. No epigenetic clock is currently recognized by major medical bodies as a diagnostic tool or a basis for clinical decision-making, and test-retest variability, meaning how much your own score fluctuates between two samples taken close together with no real biological change, is a genuine limitation that consumer-facing marketing does not always make clear. Treating a result as a rough, population-benchmarked risk signal to track alongside other health data, rather than as a precise medical measurement, is the more defensible way to use one.
Can You Actually Lower Your Biological Age?
This is the question behind most of the consumer interest, and the honest answer is probably to some degree, though the evidence for any specific intervention reversing epigenetic age is still early and mixed. A small randomized trial testing a combined diet, sleep, exercise, and supplement program in healthy men found a measurable reduction in Horvath clock-estimated age after eight weeks compared with controls, one of the first controlled human trials to report this kind of result (Fitzgerald et al., Aging, 2021), though the trial was small and needs replication before strong conclusions are warranted.
More broadly, the same behaviors with the deepest evidence for actual mortality reduction, not eating patterns and exercise routines optimized specifically to move a methylation number, remain the most defensible strategy: regular aerobic and resistance exercise, discussed in our exercise longevity protocol article, adequate high-quality sleep, covered in our sleep duration and mortality piece, and favorable cardiovascular markers such as those in our ApoB and cardiovascular longevity article. Pharmacological interventions such as metformin and rapamycin are also being studied for their effects on epigenetic age specifically, though, as with their broader longevity evidence, human data remains preliminary. An epigenetic age test is best used as a periodic checkpoint to see whether your existing health strategy appears to be working, not as the strategy itself.
What Are the Limitations and Controversies of Epigenetic Clocks?
Despite genuinely impressive mortality prediction in research cohorts, epigenetic clocks have real, acknowledged limitations. Test-retest reliability, how consistent a result is when the same person is tested twice within a short window, varies across commercial labs and clock versions, and is not always disclosed clearly to consumers. Different clocks, Horvath, Hannum, PhenoAge, GrimAge, DunedinPACE, can give meaningfully different biological age estimates for the same person, since they were built with different target variables and training populations, which is confusing for anyone expecting a single, authoritative number rather than a family of related but distinct tools measuring somewhat different things.
There is also legitimate scientific debate about mechanism: it remains unsettled how much DNA methylation changes are a cause of functional aging versus a downstream marker or byproduct of other aging processes, or some combination of both, a distinction that matters enormously for whether directly targeting methylation patterns would be expected to slow aging itself. Cost and lack of insurance coverage put routine testing out of reach for many people, and no regulatory body currently treats any clock's output as a basis for medical decisions such as changing medication or screening schedules. These are reasons for informed caution, not reasons to dismiss the field entirely. The underlying science, particularly the mortality prediction evidence behind GrimAge and PhenoAge, is considerably more robust than most commercially marketed health tests.
Frequently Asked Questions
Is an epigenetic age test accurate? For population-level mortality and disease risk prediction, the leading second-generation clocks, particularly GrimAge and PhenoAge, have shown strong, replicated accuracy across large research cohorts (Lu et al., Aging, 2019; Levine et al., Aging, 2018). For predicting a single individual's exact biological age with medical-grade precision, accuracy is more limited, since test-retest variability and differences between clock versions mean the same person can receive somewhat different scores from different tests or labs.
What is the difference between GrimAge and PhenoAge? Both are second-generation epigenetic clocks trained to predict health outcomes rather than chronological age alone. PhenoAge was built from a composite of clinical biomarkers linked to mortality risk (Levine et al., Aging, 2018). GrimAge incorporates methylation-based surrogates for smoking history and several mortality-associated plasma proteins, and has shown particularly strong performance predicting time to death and specific disease outcomes in validation studies (Lu et al., Aging, 2019). Neither is universally better; they were built with different target variables and both show strong, independent predictive value.
Can lifestyle changes actually lower my epigenetic age? Early evidence suggests it may be possible to some degree. A small randomized trial found a measurable reduction in methylation-based age after a structured eight-week diet, sleep, and exercise program (Fitzgerald et al., Aging, 2021), though this remains a preliminary finding from one small trial that needs replication in larger, more diverse populations before it can be considered well established.
How much does epigenetic age testing cost, and is it covered by insurance? Direct-to-consumer epigenetic age tests generally cost between 100 and 300 US dollars, and are not currently covered by health insurance in the United States, since no clock is recognized as a diagnostic test by major medical or regulatory bodies. Costs vary by company, sample type, and whether the test includes multiple clock estimates.
Should I get an epigenetic age test instead of standard blood work? No, the two serve different purposes and are not substitutes for each other. Standard blood work and biomarkers such as those covered in our ApoB and cardiovascular longevity article are clinically validated, actionable, and typically covered by insurance. An epigenetic age test is better thought of as an additional, research-grounded data point layered on top of standard care, alongside functional and body composition measures like grip strength and DEXA scanning, rather than a replacement for conventional medical testing.